3611 Valley Centre Drive
About Travere Therapeutics
Even with the challenges all of us are facing as a result of COVID-19, Travere Therapeutics continues to come together as an organization to live our mission each day to support our patients and invest in our capabilities for the future. At the center of these efforts are our people. Travere remains committed to preventing interruption of our clinical programs, providing unwavering patient support and ensuring delivery of therapies to our patients. Moments like this are when our patients need us the most.
If you want to join a team that now more than ever lives its mission to the fullest extent, please review our current opportunities and apply to positions that may be of interest to you.
Travere is continuing to hire for all open roles with all interviewing and onboarding done virtually due to COVID-19.
Everyone new to the team, along with our current staff, will temporarily work from home until it is safe to return to our offices.
At Travere Therapeutics, formerly Retrophin, our number one priority will always be the patients we serve - they are “why” we come to work each day. Our Why is ingrained into our culture and is paramount to “what” we do every day and “how” we do it to achieve our mission of identifying, developing and delivering life-changing therapies to people living with rare disease. By working hard, supporting our team members and living our values of Accountability, Entrepreneurial Spirit, Integrity, Patient Focus, Scientific Excellence and Teamwork, we strive to help our organization succeed and pursue our vision - to become a preeminent, global and fully-integrated biopharmaceutical company within the rare disease community that is dedicated to giving patients a chance and providing hope.
Our pipeline features late-stage development programs targeting rare diseases with significant unmet medical needs including sparsentan for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN), disorders characterized by progressive scarring of the kidney often leading to end-stage renal disease. In partnership with leaders in patient advocacy and government research, we are also working to identify potential therapeutics for NGLY1 deficiency and Alagille syndrome, rare conditions with no approved treatment options. Our R&D efforts are supported by revenues from our four commercial products Chenodal® (chenodiol), Cholbam® (cholic acid), Thiola® (tiopronin) and THIOLA EC™ (tiopronin) delayed-release tablets.
Through our portfolio of approved products and promising pipeline focused on hepatology, nephrology and neurology, we strive to help people achieve the best possible outcomes today and tomorrow. But most importantly, it is the commitment of our experienced, knowledgeable and compassionate team members, who put patients at the center of everything they do, that truly matters.
212 articles with Travere Therapeutics
Retrophin, Inc. reported its second quarter 2019 financial results and provided a corporate update.
Retrophin, Inc. announced that Eric Dube, Ph.D., chief executive officer, will present at the Canaccord Genuity 39th Annual Growth Conference in Boston on Wednesday, August 7, 2019 at 8:30 a.m. ET.
Retrophin Announces FDA Approval of THIOLA® EC (tiopronin) 100mg and 300mg Tablets for the Treatment of Cystinuria
Retrophin, Inc. announced that the U.S. Food and Drug Administration (FDA) has approved 100 mg and 300 mg tablets of THIOLA® EC (tiopronin), a new enteric-coated formulation of THIOLA® (tiopronin), to be used for the treatment of cystinuria, a rare inherited disorder that causes a buildup of cystine levels in the urine resulting in the formation of recurring cystine kidney stones.
Retrophin, Inc. announced it will report second quarter 2019 financial results on Tuesday, August 6, 2019 after the close of the U.S. financial markets.
Retrophin, based in San Diego, announced that the U.S. Food and Drug Administration (FDA) had given its 100 mg and 300 mg tablets of Thiola EC (tiopronin) the thumbs-up to treat cystinuria.
July looks to be a quiet month for the U.S. Food and Drug Administration (FDA), and it sure looks like the agency is trying to get a lot of work done before the July 4 holiday. Here’s a look at the many approvals scheduled for this week.
Two weeks after filing a lawsuit against his former company from prison, Martin Shkreli has reached a settlement with Retrophin.
Retrophin Announces Cooperative Research and Development Agreement with NCATS and the Alagille Syndrome Alliance to Identify Potential Therapeutics for Alagille Syndrome
Retrophin, Inc. announced that it has entered into a three-way Cooperative Research and Development Agreement with the National Institutes of Health’s National Center for Advancing Translational Sciences and patient advocacy foundation Alagille Syndrome Alliance to collaborate on research efforts aimed at the identification and development of potentially novel therapeutics for Alagille syndrome.
Retrophin, Inc. announced that Company management will present at the following upcoming investor conferences in June
Ms. Poole brings more than 25 years of biopharmaceutical product development and manufacturing experience to Retrophin
Retrophin, Inc. reported its first quarter 2019 financial results and provided a corporate update.
Retrophin, Inc. announced it will report first quarter 2019 financial results on Tuesday, May 7, 2019 after the close of the U.S. financial markets.
Retrophin, Inc. announced that Eric Dube, Ph.D., chief executive officer, will present at the following upcoming investor conferences in March
Retrophin Recognizes Rare Disease Day® 2019 and Honors People Living with Rare Disease and Their Caregivers
Retrophin, Inc. joins the National Organization for Rare Disorders, the European Organisation for Rare Diseases, and others worldwide to recognize Rare Disease Day® 2019.
Two pivotal Phase 3 studies of sparsentan progressing on-track to enable potential first-in-class treatment for both FSGS and IgAN
Retrophin, Inc. announced that Eric Dube, Ph.D., chief executive officer, will present at the 8th Annual SVB Leerink Global Healthcare Conference in New York Cityon Thursday, February 28, 2019 at 3:30 p.m. ET.
Retrophin, Inc. announced it will report fourth quarter and full year 2018 financial results on Tuesday, February 26, 2019 after the close of the U.S. financial markets.
Top-line readout of pivotal FORT Study in PKAN expected 3Q19
Dr. Dube brings proven track record of global leadership built upon significant commercial and operational success
Retrophin, Inc. today announced that Stephen Aselage, chief executive officer, will present at the 37th Annual J.P. Morgan Healthcare Conference in San Francisco on Thursday, January 10, 2019 at 11:00 a.m. PT (2:00 p.m. ET).